Skip to main content
. 2015 Mar 31;6:54. doi: 10.3389/fphar.2015.00054

Figure 4.

Figure 4

Pretargeted immuno-PET recorded after injection of 120 nmol of TF2 and 3 nmol of 68Ga-IMP-288 at 30 h in a patient with metastatic breast carcinoma. Immuno-PET (A,C) shows a high tumor uptake and a higher number of lesions as compared to FDG-PET (B,D).